No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]


The authors have advised that the Funding statement was missing on page 3214 of the published paper. This error was introduced by the Editorial staff during the publication process. The funding statement should read as follows:

Funding

The TARGET and ERADICATE trials were supported in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600002C; and in part by Basilea Pharmaceutica International Ltd., Basel, Switzerland. BPR-PIP-002 trial was funded by Basilea Pharmaceutica International Ltd., Basel, Switzerland.